TB-500

TB-500 — a peptide studied for tissue repair, angiogenesis, and recovery from injury.

Also known as: Thymosin Beta-4 fragment, TB4, tb-500-thymosin-beta-4, thymosin-beta-4

TB-500 is a synthetic peptide based on the active region (residues 17–23) of thymosin β4, a naturally occurring protein involved in cell migration, wound healing, and the construction of new tissue. The commercial peptide is the seven-amino-acid sequence LKKTETQ with an acetylated N-terminus — a small, focused fragment designed to capture the repair-promoting activity of the larger parent protein.

Researchers have been interested in TB-500 because thymosin β4 plays a central role in how tissue rebuilds itself after damage. The peptide is thought to influence actin, the structural scaffolding inside cells that allows them to move, divide, and reorganize during healing. Through this and related pathways, TB-500 has been associated with promoting new blood vessel growth, supporting skin and connective tissue repair, and reducing inflammation in damaged areas.

What makes TB-500 distinctive is that recent analytical work suggests its effects in the body may not come directly from the parent peptide but from short metabolites produced as it breaks down — meaning TB-500 may function partly as a precursor that releases active fragments where they're needed.

Find the best price across vendors

9 vendors carry TB-500.

Compare prices →

TB-500 and Tissue Repair

The repair-promoting reputation of TB-500 traces back to its parent molecule, thymosin β4, and the specific seven-amino-acid region it was designed around. That sequence is the part of thymosin β4 responsible for actin binding, cell migration, and wound healing — the core cellular machinery of tissue repair (3). When tissue is damaged, cells need to migrate into the wound zone, reorganize their internal scaffolding, and coordinate with neighboring cells to rebuild structure. The LKKTETQ region of thymosin β4 appears to be central to this process, which is why it was isolated and synthesized as TB-500.

A 2026 narrative review of injectable peptides in orthopaedic and sports medicine summarized the preclinical evidence: TB-500 and thymosin β4 have been shown to promote angiogenesis — the formation of new blood vessels — and to support tissue repair in laboratory studies (4). Blood supply is often the rate-limiting factor in healing connective tissue, so peptides that encourage vessel growth tend to accelerate recovery in tissues that would otherwise heal slowly. The review notes that while these preclinical findings are consistent, formal human orthopaedic trials have not yet been completed (4).

TB-500 and Wound Healing Activity

A 2024 analytical study examined what actually happens to TB-500 once it enters the body, and the findings reframed how researchers think about the peptide's mechanism (1). Using high-resolution mass spectrometry, the researchers tracked TB-500 and its breakdown products through serum, enzyme systems, and biological samples. They identified two major metabolites — Ac-LK appearing early (within the first six hours) and Ac-LKK persisting for up to 72 hours — along with a shorter intermediate, Ac-LKKTE.

When these fragments were tested in fibroblast wound healing assays, the result was unexpected: the parent TB-500 peptide itself did not produce significant wound healing activity, but the metabolite Ac-LKKTE did (1). None of the compounds showed cytotoxicity, meaning they were well tolerated by the cells. This suggests TB-500 may function as a precursor that releases an active fragment after enzymatic processing in tissue. It's a useful reframing because it explains why a peptide with a short circulating half-life can still drive longer-lasting repair effects — the active fragments persist and continue working after the parent has been cleared.

Earlier in vitro work using human liver microsomes and serum confirmed that TB-500 is rapidly processed by both endopeptidases and exopeptidases, generating multiple metabolites consistent with this fragment-release model (5).

TB-500 and Pharmacokinetics

Several studies have characterized how TB-500 behaves once administered, primarily in the context of developing detection methods for sports anti-doping. A 2012 study tracked TB-500 and its metabolites in biological samples after a single 10 mg dose, successfully identifying both the parent peptide and its breakdown products in plasma (down to 0.02 ng/mL) and urine (down to 0.01 ng/mL) (2). This was the first reported detection of TB-500 and its metabolites in post-administration samples and established that the peptide and its fragments persist in measurable form long enough to be tracked.

A 2012 characterization study confirmed that the active ingredient in commercial TB-500 preparations is the N-terminal acetylated LKKTETQ fragment of thymosin β4, synthesized via solid-phase peptide synthesis (3). The acetylation at the N-terminus appears to influence stability and activity, distinguishing TB-500 from the unacetylated form of the same sequence. Together, these studies provide a clearer picture of what TB-500 is chemically, how it's metabolized, and how long its fragments remain detectable — foundational information for understanding its potential effects on tissue.

Risks and what to know

Reported side effects in the published research are minimal. Across the laboratory and analytical studies available, no cytotoxicity was observed for TB-500 or its metabolites in fibroblast assays (1), and no significant adverse effects have been documented in the limited in vivo work. Long-term safety in humans hasn't been formally characterized because the necessary large-scale trials haven't been completed.

The body of TB-500 evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far (4).

TB-500 is a banned substance under World Anti-Doping Agency rules and is prohibited in most professional and amateur sports — relevant context for competitive athletes, since both the parent peptide and its metabolites can be detected in plasma and urine for extended periods after administration (2).

References

1.Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B 2024. PubMed →
2.Ho ENM, Kwok WH, Lau MY, Wong ASY, Wan TSM, Lam KKH, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A 2012. PubMed →
3.Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis 2012. PubMed →
4.Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Hatch GFR, Gamradt SC, Weber AE. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine 2026. PubMed →
5.Esposito S, Deventer K, Geldof L, Van Eenoo P. In vitro models for metabolic studies of small peptide hormones in sport drug testing. Journal of Peptide Science 2015. PubMed →

Latest research

Auto-updated as new studies are published. Last refresh: May 2026.

Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5.

Analytical biochemistry · 2017 · Journal Article

This analytical chemistry study directly investigated TB-500 as one of four doping-relevant model peptides, evaluating its adsorption behavior to various laboratory surfaces (glassware and plasticware) at low concentrations (ng/mL–pg/mL range). The research focuses on analytical recovery methodology rather than biological effects, finding that low-bind consumables are not universally beneficial and that selection should be based on the physicochemical properties of each peptide. This study contributes practical information about handling and measuring TB-500 in anti-doping analytical contexts, but does not examine the peptide's biological activity or pharmacology.

All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

TB-500

Find the best price across vendors

TB-500 and Tissue Repair

TB-500 and Wound Healing Activity

TB-500 and Pharmacokinetics

Risks and what to know

References

Latest research

Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5.

Related peptides

PT-141

Epitalon

Hexarelin

Melanotan 2